Investor center

March 23. 2026
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420

Read more

Our future growth and value generation is based on increasing revenues from our two marketed anti-infectives and our innovative pipeline

Investing in Basilea

Positioned for sustained growth and increasing value

  1. Profitable commercial-stage company with two marketed anti-infective products
  2. Strong financial position with sustainable cash flows supporting continued growth
  3. Leading strategic position in an area of high unmet medical need, addressing rising challenges in treating severe bacterial and fungal infections
  4. Current Phase 3 pipeline assets alone create opportunity to double 2025 in-market sales
  5. Proven, capital‑efficient and asset-light business model leveraging strong global partnerships

Current presentation

Updated March 23, 2026

Download

 

 

 

 

 

Highlights Financial Reports

Full-year 2025 Update by Basilea CEO, David Veitch
Half-year 2025 Update by Basilea CEO, David Veitch
Basilea: Highlights of Annual Report 2024
Full-year 2024 Update by Basilea CEO, David Veitch
Half-year 2024 Update by Basilea CEO, David Veitch

Events and presentations

Mar 31. 2026
HealthCare Investors Meeting
Genolier, Switzerland
Apr 08. 2026
Investor Access Event Paris
Paris, France
May 13. 2026
Annual Kepler Cheuvreux Swiss Seminar
Virtual, Switzerland
Jul 02. 2026
Bank of America Convertible Bonds Conference
London, United Kingdom
Oct 28. 2026
Capital Markets Day 2026
Zurich, Switzerland

 

Archive

Annual General Meeting

Analyst coverage

The analysts listed on this page have published reports or commentary on Basilea; there may be other analysts who have published reports or commentary that are not referenced here.  Please note that any opinions, estimates or forecasts regarding Basilea's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Basilea or its management.  Basilea does not by its reference on this website imply any endorsement of or concurrence with such information, conclusions or recommendations.

FIRMANALYST
Baader Helvea AGMartin Schnee
Calvine Partners LLPBrian White
Edison Investment Research Ltd.Jyoti Prakash
H. C. Wainwright & Co.Raghuram Selvaraju
Kepler CheuvreuxChristophe Dombu
Pareto Securities ABChien-Hsun Lee & Dan Akschuti
Zürcher KantonalbankJasmin Spörri

 

Share information

Convertible bonds

In July 2020, Basilea issued CHF 97.085 million aggregate principal amount of convertible senior unsecured bonds (the “2027 Bonds”, ISIN: CH0554992062; SSN: 55'499'206). The 2027 Bonds bear interest at a fixed rate of 3.25% per year and mature on July 28, 2027, unless earlier redeemed or converted. As of December 31, 2025, following the repurchase of a portion of the bonds, CHF 75.440 million remain outstanding. For further information on the outstanding bonds, please refer to the current annual report.

Sustainability (ESG)

At Basilea, we have performed a materiality analysis in 2023 that helped us to understand, which environmental, social, governance (ESG) and economic topics matter most in the context of Basilea’s business model. These material topics form the basis of our ESG strategy. They are key for the setting of goals and are at the core of our ESG-related reporting. In 2024, we further developed our ESG strategy by defining KPIs for the individual focus topics. In 2025, a first sustainability report was developed in accordance with the GRI Standards and published as part of the full-year report 2025.

ESG report 2025

Key elements of Basilea's ESG strategy - update 2024

Key elements of Basilea's ESG strategy - initial release 2023

Corporate Governance